Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198072 | 0.89 | PPARG (0.34) | NPC1RAB9AICAM1SELEPPARA | |
| SCHEMBL12876196 | 0.86 | KDM4C (0.33) | NPC1RAB9AICAM1SELEPPARA | |
| SCHEMBL15006436 | 0.85 | NPC1 (0.31) | NPC1RAB9APPARAPPARG | |
| SCHEMBL12876224 | 0.83 | PPARG (0.32) | NPC1RAB9AICAM1SELEPPARA | |
| SCHEMBL12876153 | 0.77 | FFAR1 (0.38) | NPC1RAB9AICAM1SELEPPARA | |
| SCHEMBL1197708 | 0.77 | PPARG (0.34) | NPC1RAB9APPARAPPARGKDM4C | |
| SCHEMBL13650689 | 0.75 | TACR1 (0.31) | PPARAPPARG | |
| SCHEMBL1199086 | 0.74 | PPARG (0.36) | ICAM1SELEPPARAPPARGKDM4C | |
| SCHEMBL4807747 | 0.74 | KDM4C (0.39) | ICAM1SELEKDM4C | |
| SCHEMBL22279030 | 0.73 | CREBBP (0.39) | NPC1RAB9AICAM1SELEKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | NPC1 3877/4885RAB9A 2507/4885ICAM1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.